Phaseline

Targets › STMN1

STMN1 (Stathmin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Oncology; next expected readout Dec 2033.

Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. Prevents assembly and promotes disassembly of microtubules. (UniProt, P16949)

Open in Phaseline: the race on STMN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Haukeland University HospitalBiomarker guided weekly taxane treatment
Stathmin-guided taxane chemotherapy based on tissue biomarker analysis
STMN1Phase 4Endometrial CancerDec 2033

Conditions

Endometrial Cancer (1)

Modalities

small molecule (1)

Companies

Haukeland University Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.